Introducing new antimalarial analogues of chloroquine and amodiaquine: A narrative review

Iranian Journal of Medical Sciences

Volumn 42, Issue 2, 2017, Pages 115-128

  Parhizgar, Arezoo Rafiee ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Amodiaquine; Chloroquine; Drug resistance; Malaria

Indexed keywords

AMODIAQUINE; CHLOROQUINE; MEFLOQUINE; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ACIDITY; AGRANULOCYTOSIS; ANTIMALARIAL ACTIVITY; ANTIPLASMODIAL ACTIVITY; CELL VACUOLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG TOLERABILITY; HUMAN; LIFE CYCLE; LIPID SOLUBILITY; LIPOPHILICITY; LIVER TOXICITY; MACROPHAGE; MALARIA; MALARIA CONTROL; NONHUMAN; NUCLEOPHILICITY; PARASITE LOAD; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; REVIEW; SPOROZOITE;

EID: 85014788642     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. World Health Organization. Antimicrobial resistance: Global report on surveillance 2014. Geneva: WHO; 2014. 257 p.
2. Winzeler EA. Malaria research in the postgenomic era. Nature. 2008;455:751-6. doi: 10.1038/nature07361.
3. Flannery EL, Chatterjee AK, Winzeler EA. Antimalarial drug discovery - approaches and progress towards new medicines. Nat Rev Microbiol. 2013;11:849-62. doi: 10.1038/nrmicro3138.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Arlington: American Psychiatric Association publishing; 2013. 29 p.
5. Jensen M, Mehlhorn H. Seventy-five years of Resochin in the fight against malaria. Parasitol Res. 2009;105:609-27. doi: 10.1007/s00436-009-1524-8.
6. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies. Pharmacogenomics. 2009;10:1489-510. doi: 10.2217/pgs.09.82.
7. Wells TN, Poll EM. When is enough enough? The need for a robust pipeline of high-quality antimalarials. Discov Med. 2010;9:389-98.
8. Winstanley PA, Ward SA, Snow RW. Clinical status and implications of antimalarial drug resistance. Microbes Infect. 2002;4:157-64. doi: 10.1016/S1286-4579(01)01523-4.
9. Tahghighi A. Importance of metal complexes for development of potential leishmanicidal agents. J Organomet Chem. 2014;770:51-60. doi: 10.1016/j.jorganchem.2014.08.007.
10. Rosenthal PJ. Antimalarial chemotherapy: Mechanisms of action, resistance, and new directions in drug discovery. New York: Springer Science & Business Media; 2001. 396 p.
11. Hastings IM. The origins of antimalarial drug resistance. Trends Parasitol. 2004;20:512-8. doi: 10.1016/j.pt.2004.08.006.
12. Golan DE, Tashjian AH, Armstrong EJ. Principles of pharmacology: The pathophysiologic basis of drug therapy. Philadelphia: Lippincott Williams & Wilkins; 2011. 1008 p.
13. D’Alessandro U, Buttiens H. History and importance of antimalarial drug resistance. Trop Med Int Health. 2001;6:845-8. doi: 10.1046/j.1365-3156.2001.00819.x.
14. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298:210-3. doi: 10.1126/science.1074045.
15. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861-71. doi: 10.1016/S1097-2765(05)00077-8.
16. Sanchez CP, Stein WD, Lanzer M. Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum. Trends Parasitol. 2007;23:332-9. doi: 10.1016/j.pt.2007.04.013.
17. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K. Chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Science. 2009;325:1680-2. doi: 10.1126/science.1175667.
18. Bray PG, Mungthin M, Hastings IM, Biagini GA, Saidu DK, Lakshmanan V, et al. PfCRT and the trans-vacuolar proton electrochemical gradient: Regulating the access of chloroquine to ferriprotoporphyrin IX. Mol Microbiol. 2006;62:238-51. doi: 10.1111/j.1365-2958.2006.05368.x.
19. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci. 2006;27:594-601. doi: 10.1016/j.tips.2006.09.005.
20. Anderson TJ, Nair S, Qin H, Singlam S, Brockman A, Paiphun L, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother. 2005;49:2180-8. doi: 10.1128/AAC.49.6.2180-2188.2005.
21. Sanchez CP, Rotmann A, Stein WD, Lanzer M. Polymorphisms within PfMDR1 alter the substrate specificity for antimalarial drugs in Plasmodium falciparum. Mol Microbiol. 2008;70:786-98. doi: 10.1111/j.1365-2958.2008.06413.x.
22. Shimizu S, Atsumi R, Itokawa K, Iwasaki M, Aoki T, Ono C, et al. Metabolism-dependent hepatotoxicity of amodiaquine in glutathionedepleted mice. Arch Toxicol. 2009;83:701-7. doi: 10.1007/s00204-009-0436-9.
23. Tafazoli S, O’Brien PJ. Amodiaquine-induced oxidative stress in a hepatocyte inflammation model. Toxicology. 2009;256:101-9. doi: 10.1016/j.tox.2008.11.006.
24. Reyburn H. New WHO guidelines for the treatment of malaria. BMJ. 2010;340:c2637. doi: 10.1136/bmj.c2637.
25. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959-66. doi: 10.1056/NEJMoa062032.
26. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, et al. A molecular marker for chloroquineresistant falciparum malaria. N Engl J Med. 2001;344:257-63. doi: 10.1056/NEJM200101253440403.
27. Read AF, Huijben S. Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl. 2009;2:40-51. doi: 10.1111/j.1752-4571.2008.00066.x.
28. Saenz FE, Mutka T, Udenze K, Oduola AM, Kyle DE. Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro. Antimicrob Agents Chemother. 2012;56:4685-92. doi: 10.1128/AAC.01061-12.
29. Ramanathan-Girish S, Catz P, Creek MR, Wu B, Thomas D, Krogstad DJ, et al. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. Int J Toxicol. 2004;23:179-89. doi: 10.1080/10915810490471352.
30. Navarro M, Castro W, Martinez A, Sanchez Delgado RA. The mechanism of antimalarial action of [Au(CQ)(PPh(3))] PF(6): Structural effects and increased drug lipophilicity enhance heme aggregation inhibition at lipid/water interfaces. J Inorg Biochem. 2011;105:276-82. doi: 10.1016/j.jinorgbio.2010.11.005.
31. Martinez A, Rajapakse CS, Naoulou B, Kopkalli Y, Davenport L, Sanchez-Delgado RA. The mechanism of antimalarial action of the ruthenium(II)-chloroquine complex [RuCl(2)(CQ)] (2). J Biol Inorg Chem. 2008;13:703-12. doi: 10.1007/s00775-008-0356-9.
32. Pradines B, Fusai T, Daries W, Laloge V, Rogier C, Millet P, et al. Ferrocenechloroquine analogues as antimalarial agents: In vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J Antimicrob Chemother. 2001;48:179-84. doi: 10.1093/jac/48.2.179.
33. Biot C, Nosten F, Fraisse L, Ter-Minassian D, Khalife J, Dive D. The antimalarial ferroquine: From bench to clinic. Parasite. 2011;18:207-14. doi: 10.1051/parasite/2011183207.
34. Dubar F, Khalife J, Brocard J, Dive D, Biot C. Ferroquine, an ingenious antimalarial drug: Thoughts on the mechanism of action. Molecules. 2008;13:2900-7. doi: 10.3390/molecules13112900.
35. Barends M, Jaidee A, Khaohirun N, Singhasivanon P, Nosten F. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar J. 2007;6:81. doi: 10.1186/1475-2875-6-81.
36. Leimanis ML, Jaidee A, Sriprawat K, Kaewpongsri S, Suwanarusk R, Barends M, et al. Plasmodium vivax susceptibility to ferroquine. Antimicrob Agents Chemother. 2010;54:2228-30. doi: 10.1128/AAC.01572-09.
37. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: A resurgent antimalarial drug. Drugs. 2005;65:75-87. doi: 10.2165/00003495-200565010-00004.
38. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004;57:253-62. doi: 10.1046/j.1365-2125.2003.02004.x.
39. Zwang J, Ashley EA, Karema C, D’Alessandro U, Smithuis F, Dorsey G, et al. Safety and efficacy of dihydroartemisininpiperaquine in falciparum malaria: A prospective multi-centre individual patient data analysis. PLoS One. 2009;4:e6358. doi: 10.1371/journal.pone.0006358.
40. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother. 2007;51:4090-7. doi: 10.1128/AAC.00486-07.
41. Snyder C, Chollet J, Santo-Tomas J, Scheurer C, Wittlin S. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp Parasitol. 2007;115:296-300. doi: 10.1016/j.exppara.2006.09.016.
42. Benoit-Vical F, Lelievre J, Berry A, Deymier C, Dechy-Cabaret O, Cazelles J, et al. Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob Agents Chemother. 2007;51:1463-72. doi: 10.1128/AAC.00967-06.
43. Cosledan F, Fraisse L, Pellet A, Guillou F, Mordmuller B, Kremsner PG, et al. Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci U S A. 2008;105:17579-84. doi: 10.1073/pnas.0804338105.
44. Rudrapal M, Chetia D. Novel 4-aminoquinoline analogues as antimalarial agents: A review. Der Pharma Lett. 2011;3:29-36.
45. Burgess SJ, Kelly JX, Shomloo S, Wittlin S, Brun R, Liebmann K, et al. Synthesis, structure-activity relationship, and modeof-action studies of antimalarial reversed chloroquine compounds. J Med Chem. 2010;53:6477-89. doi: 10.1021/jm1006484.
46. Lodige M, Hiersch L. Design and Synthesis of Novel Hybrid Molecules against Malaria. Int J Med Chem. 2015;2015:458319. doi: 10.1155/2015/458319.
47. Solomon VR, Haq W, Srivastava K, Puri SK, Katti SB. Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives. J Med Chem. 2007;50:394-8. doi: 10.1021/jm061002i.
48. Musonda CC, Gut J, Rosenthal PJ, Yardley V, Carvalho de Souza RC, Chibale K. Application of multicomponent reactions to antimalarial drug discovery. Part 2: New antiplasmodial and antitrypanosomal 4-aminoquinoline gamma- and deltalactams via a ‘catch and release’ protocol. Bioorg Med Chem. 2006;14:5605-15. doi: 10.1016/j.bmc.2006.04.035.
49. Perez BC, Teixeira C, Albuquerque IS, Gut J, Rosenthal PJ, Gomes JR, et al. N-cinnamoylated chloroquine analogues as dual-stage antimalarial leads. J Med Chem. 2013;56:556-67. doi: 10.1021/jm301654b.
50. Tasso B, Novelli F, Tonelli M, Barteselli A, Basilico N, Parapini S, et al. Synthesis and Antiplasmodial Activity of Novel Chloroquine Analogues with Bulky Basic Side Chains. ChemMedChem. 2015;10:1570-83. doi: 10.1002/cmdc.201500195.
51. O’Neill PM, Shone AE, Stanford D, Nixon G, Asadollahy E, Park BK, et al. Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4’-fluoro and 4’-chloro analogues of amodiaquine. Identification of a suitable “back-up” compound for N-tert-butyl isoquine. J Med Chem. 2009;52:1828-44. doi: 10.1021/jm8012757.
52. Casagrande M, Basilico N, Parapini S, Romeo S, Taramelli D, Sparatore A. Novel amodiaquine congeners as potent antimalarial agents. Bioorg Med Chem. 2008;16:6813-23. doi: 10.1016/j.bmc.2008.05.068.
53. Paunescu E, Susplugas S, Boll E, Varga RA, Mouray E, Grellier P, et al. Synthesis and antimalarial activity of new amino analogues of amodiaquine. Med Chem. 2008;4:407-25. doi: 10.2174/157340608785700153.
54. O’Neill PM, Mukhtar A, Stocks PA, Randle LE, Hindley S, Ward SA, et al. Isoquine and related amodiaquine analogues: A new generation of improved 4-aminoquinoline antimalarials. J Med Chem. 2003;46:4933-45. doi: 10.1021/jm030796n.
55. Delarue S, Girault S, Maes L, Debreu-Fontaine MA, Labaeid M, Grellier P, et al. Synthesis and in vitro and in vivo antimalarial activity of new 4-anilinoquinolines. J Med Chem. 2001;44:2827-33. doi: 10.1021/jm010842o.
56. O’Neill PM, Park BK, Shone AE, Maggs JL, Roberts P, Stocks PA, et al. Candidate selection and preclinical evaluation of N-tertbutyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J Med Chem. 2009;52:1408-15. doi: 10.1021/jm8012618.
57. Miroshnikova OV, Hudson TH, Gerena L, Kyle DE, Lin AJ. Synthesis and antimalarial activity of new isotebuquine analogues. J Med Chem. 2007;50:889-96. doi: 10.1021/jm061232x.
58. Ongarora DS, Gut J, Rosenthal PJ, Masimirembwa CM, Chibale K. Benzoheterocyclic amodiaquine analogues with potent antiplasmodial activity: Synthesis and pharmacological evaluation. Bioorg Med Chem Lett. 2012;22:5046-50. doi: 10.1016/j.bmcl.2012.06.010.
59. Saha CN, Bhattacharya S, Chetia D. Synthesis and Antimalarial Screening of Some New Isoquine Analogues. International Journal of ChemTech Research. 2009;1:322-8.
60. Guglielmo S, Bertinaria M, Rolando B, Crosetti M, Fruttero R, Yardley V, et al. A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. Eur J Med Chem. 2009;44:5071-9. doi: 10.1016/j.ejmech.2009.09.012.
61. Bertinaria M, Guglielmo S, Rolando B, Giorgis M, Aragno C, Fruttero R, et al. Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. Eur J Med Chem. 2011;46:1757-67. doi: 10.1016/j.ejmech.2011.02.029.
62. Hochart G, Paunescu E, Boll E, Melnyk P. PM6280 and PM6577: ADME Study of Two Potent and Anti-malarial Amodiaquine Analogs with Improved Metabolic Stability. Research & Reviews: Journal of Medicinal & Organic Chemistry. 2015;2:1-14.